


# Investor's Presentation



Presentation 2025



# Table Of Contents

- Company Overview
- New Plant
- Evolution of API Products
- KEY PRODUCTS
- Pharmaceutical Strategy.
- Key Goals
- Main Areas of Operation
- Model and Roadmap
- CAPACITY AND UTILISATION
- Proven Track Record
- Financials
- OUR CLIENTS
- About Our Team
- SAFE HARBOR STATEMENT
- Thank You



# Company Overview

- Syschem (India) Limited (SIL) is a listed company engaged in the manufacturing of Bulk Drugs/Intermediates and contract manufacturing. It is owned and operated by a highly committed group of techno commercial with extensive experience in the bulkdrug business.





- The Company is committed to its highly committed team of techno-commercial specialists with considerable expertise in the bulk medicine market. Syschem India Limited has established a firm presence in the business by providing their consumers with high-quality products and services.
- The Company's commitment to research and development, quality assurance, and customer satisfaction has established it as a trusted partner in the pharmaceutical business.





# NEW PLANT





# THE EVOLUTION FOR API PRODUCTS





# KEY PRODUCTS

01

## AMOXICILLIN

A broad-spectrum penicillin antibiotic used to treat bacterial infections



## AMPICILLIN


A penicillin antibiotic effective against both gram-positive and some gram-negative bacteria.

02

03

## CLOXACILLIN

A penicillinase-resistant penicillin used mainly for staphylococcal infections.



## DICLOXACILLIN

A beta-lactam antibiotic used to treat infections caused by penicillinase-producing staphylococci.

04

05

## FLUCLOXACILLIN

A narrow-spectrum penicillin effective against penicillin-resistant staphylococci.



## CEPHALEXIN

A first-generation cephalosporin antibiotic used for skin, respiratory, and urinary tract infections.

06

07

## CEPHADROXIL

A first-generation cephalosporin antibiotic used for skin, throat, and urinary infections.



AGENDA



# Pharmaceutical Strategy

**Innovating for Future  
Success**



**AGENDA**



# STRATEGIC VISION & EVOLUTION

## OUR DIRECTION


- 1 Largely the capacity expansions
- 2 Increase in distribution network
- 3 Adding Product Ranges





# Our Strategic Vision Explained

SIL's vision is to boost production of our existing products while expanding our offers by creating various intermediates that are now imported from China for the API industry. Over the next 2-3 years, we hope to minimise our reliance on imports and attain more self-sufficiency. To accomplish this, we recognise the need to increase our facilities and machinery. We feel that this investment will help us achieve our goal and position us for long-term success.





## **HIGH GROWTH POTENTIAL & SHAREHOLDER VALUE CREATION**

Our company's rapid growth—fueled by innovation, global expansion, and robust product pipelines—demonstrates our ability to meet rising healthcare demands and successfully enter new markets. This sustained momentum translates into strong shareholder value through increased revenue, improved profitability, and enhanced stock performance, positioning us as an attractive long-term investment.





"We aim to drive year-on-year growth in production to meet our strategic objectives."



AGENDA





**YoY improved quality.**



**Improved market position  
on YoY basis.**



**Built up new plant of  
amoxicilin and ampicilin ,  
according to WHO GMP.**



**Planning to enter in  
international market with  
necessary approvals.**




# KEY GOALS 2023-25




# Main Areas of Operation

The company has a diverse range of intermediate items in the pharmaceuticals industry that are created chemically. The company has established a foothold in India and the international market; its products have been exported to Latin America, Africa, Thailand, Sri Lanka, Nepal, Indonesia, Germany, Bangladesh, and the MENA area.

## SUPPLY ZONE




Syschem's expansive supply chain network is a testament to its commitment to excellence and reliability. Operating across 12 Indian states and reaching over seven international locations, Syschem has established itself as a formidable player in the global market. This extensive reach ensures that the company can efficiently meet the diverse needs of its customers, maintaining a seamless flow of high-quality products






# Main Areas of Operation



## SUPPLY ZONE




Expanding operations and improving customer satisfaction are core goals for any thriving business. As we continue to grow, our focus remains on understanding and anticipating the needs of our customers, ensuring that we deliver unparalleled service and quality. This expansion involves not just increasing our geographical footprint, but also enhancing our product offerings and service channels to be more accessible and innovative.

**AGENDA**



# Innovation Roadmap Journey



## Business Model Evolution

Operated under a contract manufacturing model due to financial constraints (FY 2019–2020). Achieved debt-free status by 2022, marking a key financial recovery milestone

## Strategic Shift to Independent Sales

Transitioned from contract manufacturing to independent sales operations in India and select global markets. Backed by strong promoter support and strategic decision-making. Marked the beginning of brand-building and direct market engagement.

## Performance Highlights

Recorded highest-ever topline revenue in the last financial year. Bottom-line growth challenged by intense price competition and new market entry barriers. Faced difficulties in acquiring competitor-served customers.

## Current Position & Future Outlook

Built a strong customer base and improved market confidence. Focused on operational efficiency, market penetration, and regulatory excellence. Poised for sustainable growth and justified profitability in the coming years.



# PROVEN TRACK RECORD OF PRODUCTION


**Excellence in Delivery** Every Time






# Proven Track Record of Topline



Showcasing consistent growth strategies



## AGENDA







# CAPACITY AND UTILISATION


AGENDA





# EBIDTA

2022-23 2023-24 2024-25



PBT PAT

700

600

500

400

300

200

100

0

2022-23

2023-24

2024-25

# FINANCIALS

AGENDA





# OUR CLIENTS




Medico Remedies Ltd

AGENDA



# About Our Team

The people behind the company's achievements



At the heart of our pharmaceutical company lies an exceptional team that embodies innovation, collaboration, and commitment to excellence. Our diverse group of professionals, ranging from researchers and scientists to marketing experts and regulatory specialists, work tirelessly to advance healthcare solutions that improve lives.



"The remarkable expansion in revenue has characterised our pharmaceutical company specialising in API production, propelled by our dedication to delivering high-quality, cost-effective products that address the needs of our clientele and foster improved health outcomes."



# SAFE HARBOR STATEMENT

This Information Memorandum has been prepared by the Company based on information and data which the Company considers reliable. However, the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, reliability, or fairness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of or any omission from this Presentation is expressly excluded. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Presentation or in relation to the bases and assumptions underlying such projections. You must satisfy yourself in relation to the reasonableness, achievability, and accuracy thereof.

AGENDA



Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the wind power industry in India and worldwide, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences, and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance, or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company, and the Company is not responsible for such third-party statements and projections.

No responsibility or liability is accepted for any loss or damage, howsoever arising, that you may suffer as a result of this Presentation. All responsibility and liability are expressly disclaimed by the Management, the Shareholders, and the Company or any of them or any of their respective directors, officers, affiliates, employees, advisers, or agents.

## AGENDA



# THANK YOU

A Presentation by -



AGENDA

Factory at. : Village Bargodam, Tehsil Kalka, Dist. Panchkula, Haryana-133302

Corp Office. : 825, FF, NAC Manimajra , Chandigarh-161001

Telephone no : 0172-5070471

Email Id : [info@syschem.in](mailto:info@syschem.in)